Modality
Radioligand
MOA
STINGag
Target
PSMA
Pathway
Cell Cycle
LGS
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
Jun 2020
→ Jun 2027
Phase 2Current
NCT04507591
2,166 pts·LGS
2021-08→2026-08·Active
NCT03228469
1,881 pts·LGS
2020-06→2027-06·Not yet recruiting
4,047 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-034mo awayPh2 Data· LGS
2027-06-021.2y awayPh2 Data· LGS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Not yet…
P2
Active
Catalysts
Ph2 Data
2026-08-03 · 4mo away
LGS
Ph2 Data
2027-06-02 · 1.2y away
LGS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04507591 | Phase 2 | LGS | Active | 2166 | HAM-D |
| NCT03228469 | Phase 2 | LGS | Not yet recr... | 1881 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |